ArticleClinical and translational science2025
Using a PBPK Model Incorporating Lymphatic Absorption to Predict Food Effect, Multiple Dosing, and Hepatic Impairment of Cannabidiol.
Article in Clinical and translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Using a PBPK Model Incorporating Lymphatic Absorption to Predict Food Effect, Multiple Dosing, and Hepatic Impairment of Cannabidiol.Clinical and translational science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cannabidiol (CBD) is one of the most extensively studied cannabinoids and is used for myriad conditions. Its oral pharmacokinetics are complex, exhibiting non-linear absorption, significant food effects, and variable exposure in hepatic impairment. Existing physiologically based pharmacokinetic (PBPK) models for oral CBD have largely relied on fitted first-order absorption or fitted dissolution profiles, limiting their mechanistic and predictive capabilities and extrapolation, particularly regarding the mechanistic details of its absorption. This study developed and verified the first PBPK model for oral CBD with mechanism-based oral absorption based on our prior published PBPK model. It incorporated mechanism-based absorption using the multi-layer gut wall within the advanced dissolution, absorption, and metabolism (M-ADAM) model within Simcyp. Pharmacokinetic parameters for CBD or population parameters related to absorption were obtained from the literature or optimized. Some physiological parameters (e.g., luminal bile salt and lymph flow rate) were adjusted mechanistically to account for CBD's sesame oil formulation and meal characteristics. The model well captured the CBD concentration-time profiles and key pharmacokinetic parameters, including area under the concentration-time curve (AUC), peak concentration (C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.